About gemcitabin e hydrochlo
Antineoplastic nucleoside analogue
Used for
- Pancreatic cancer
- Non-small-cell lung cancer
- Ovarian cancer
- Bladder cancer
Usual adult dose
Regimens vary by cancer and combination; commonly 1,000–1,250 mg/m² by intravenous infusion on scheduled treatment days.
Common side effects
- Low blood counts and increased infection risk
- Nausea and vomiting
- Fatigue and fever
- Liver enzyme changes
Important warnings
- Can cause severe bone-marrow suppression and serious infections.
- Rarely causes serious lung, liver, kidney, or blood-vessel complications.
- Treatment requires blood-count and organ-function monitoring.
- Doses and schedules depend on cancer type and other medicines.
Pregnancy
May harm an unborn baby. Avoid during pregnancy unless specialist assessment determines treatment is necessary.
Breastfeeding
Breastfeeding is not recommended during treatment and for at least one week after the final dose.
Interactions
- Radiotherapy may increase tissue toxicity, especially when given concurrently.
- Other medicines that suppress bone marrow may increase blood-count problems.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.